NDC 51754-1210

Bloxiverz

Neostigmine Methylsulfate

Bloxiverz is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Exela Pharma Sciences, Llc. The primary component is Neostigmine Methylsulfate.

Product ID51754-1210_01a3c204-e31a-4d0b-bb9f-5877b44c2dba
NDC51754-1210
Product TypeHuman Prescription Drug
Proprietary NameBloxiverz
Generic NameNeostigmine Methylsulfate
Dosage FormInjection
Route of AdministrationINTRAVENOUS
Marketing Start Date2013-07-24
Marketing CategoryNDA /
Application NumberNDA204078
Labeler NameExela Pharma Sciences, LLC
Substance NameNEOSTIGMINE METHYLSULFATE
Active Ingredient Strength1 mg/mL
Pharm ClassesCholinesterase Inhibitor [EPC],Cholinesterase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 51754-1210-3

10 CARTON in 1 PACKAGE (51754-1210-3) > 1 VIAL, MULTI-DOSE in 1 CARTON (51754-1210-1) > 10 mL in 1 VIAL, MULTI-DOSE
Marketing Start Date2013-07-24
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Bloxiverz" or generic name "Neostigmine Methylsulfate"

NDCBrand NameGeneric Name
51754-1210BloxiverzNeostigmine Methylsulfate
51754-1220BloxiverzNeostigmine Methylsulfate
51754-1240Bloxiverzneostigmine methylsulfate
68001-329BloxiverzBloxiverz
76014-002BloxiverzBloxiverz
76014-902BloxiverzBloxiverz
76014-003BloxiverzBloxiverz
76014-903BloxiverzBloxiverz
0404-9925NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
0517-1133Neostigmine MethylsulfateNeostigmine Methylsulfate
0517-1134Neostigmine MethylsulfateNeostigmine Methylsulfate
0548-9601NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
0548-9602NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
0641-6149Neostigmine MethylsulfateNeostigmine Methylsulfate
0641-6150Neostigmine MethylsulfateNeostigmine Methylsulfate
0641-6240Neostigmine MethylsulfateNeostigmine Methylsulfate
14445-413NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
14445-414NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
23155-517Neostigmine MethylsulfateNeostigmine Methylsulfate
23155-518Neostigmine MethylsulfateNeostigmine Methylsulfate
25021-610Neostigmine MethylsulfateNeostigmine Methylsulfate
25021-611Neostigmine MethylsulfateNeostigmine Methylsulfate
31722-994neostigmine methylsulfateneostigmine methylsulfate
31722-995neostigmine methylsulfateneostigmine methylsulfate
42023-188NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
42023-189NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
43598-945Neostigmine MethylsulfateNeostigmine Methylsulfate
50090-4532NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
50090-5197Neostigmine methylsulfateNeostigmine methylsulfate
51662-1557NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
52584-057NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate

Trademark Results [Bloxiverz]

Mark Image

Registration | Serial
Company
Trademark
Application Date
BLOXIVERZ
BLOXIVERZ
85686242 4433582 Live/Registered
Éclat Pharmaceuticals, LLC
2012-07-25
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.